Skip to main content

Table 1 Descriptive statistics for all demographic, anthropometric and disease-related outcomes in patients with axial spondyloarthritis (n = 170)

From: Widespread pain in axial spondyloarthritis: clinical importance and gender differences

Variables

Total group (n = 170)

Men (n = 108)

Women (n = 62)

 

Mean (SD)

Med (IQR)

Mean (SD)

Med (IQR)

Mean (SD)

Med (IQR)

p Value

Age, yr

42.9 (12.2)

42.7 (20.3)

43.8 (12.5)

43.2 (20.4)

41.3 (11.5)

42.1 (18.0)

.199

Disease duration, yr

13.1 (11.1)

10.7 (16.6)

14.0 (11.2)

11.9 (18.4)

11.5 (11.0)

8.8 (13.0)

.155

Height, cm

171.6 (9.4)

172.3 (12.9)

176.2 (7.1)

176.2 (9.1)

163.7 (7.4)

163.4 (9.5)

< .00

Weight, kg

77.0 (15.0)

76.6 (20.9)

81.7 (13.9)

80.5 (19.2)

69.7 (13.4)

67.0 (18.1)

< .00

BMI, kg/m2

26.1 (4.4)

25.6 (6.4)

26.3 (4.4)

25.5 (6.1)

25.7 (4.4)

25.7 (7.1)

.408

BASDAI (0–10)

3.8 (2.1)

3.7 (3.3)

3.6 (2.2)

3.5 (3.5)

4.3 (2.0)

4.2 (3.1)

.027

PGDA (0–10) (n = 146)

1.4 (1.8)

1.0 (2.0)

1.4 (1.9)

0.9 (2.0)

1.4 (1.6)

1.0 (1.6)

.583

CRP, mg/L (n = 141)

8.3 (16.0)

2.9 (6.6)

8.9 (16.5)

3.0 (6.6)

7.4 (15.3)

2.2 (6.7)

.810

BASFI (0–10)

3.6 (2.4)

3.4 (3.8)

3.5 (2.4)

3.2 (4.0)

3.8 (2.3)

3.7 (3.7)

.459

BASMI (0–10)

3.0 (1.8)

2.8 (2.0)

3.3 (2.0)

2.8 (2.8)

2.6 (1.2)

2.6 (1.6)

.002

Cervical rotation, degrees

60.5 (19.6)

65.0 (25.0)

58.0 (21.3)

62.5 (27.8)

65.0 (15.6)

66.0 (20.5)

.015

Tragus to wall, cm

13.6 (4.6)

11.7 (4.5)

14.9 (5.0)

13.3 (6.2)

11.4 (2.3)

10.8 (1.8)

< .00

Lateral flexion, cm

12.4 (5.1)

12.7 (8.1)

11.7 (6.1)

12.1 (9.4)

13.5 (4.2)

13.1 (6.1)

.028

Intermalleolar distance, cm

99.0 (22.6)

103.3 (25.1)

101.0 (21.4)

105.2 (25.2)

95.5 (24.2)

100.7 (25.0)

.141

Modified Schober, cm

5.3 (2.1)

5.5 (2.5)

4.9 (2.3)

5.2 (3.1)

5.9 (1.7)

6.2 (2.0)

.002

TSK-11 (11–44)

24.8 (6.3)

25.0 (10.0)

27.8 (6.4)

25.0 (10.0)

24.9 (6.0)

25.0 (9.3)

.888

HADS depression (0–21)

4.6 (3.6)

4.0 (5.0)

4.8 (3.7)

4.0 (5.0)

4.4 (3.5)

3.0 (4.0)

.580

HADS anxiety (0–21)

7.1 (3.6)

7.0 (5.0)

6.7 (3.4)

7.0 (5.0)

7.8 (3.9)

7.5 (5.0)

.071

Frequencies (%)

Gender, male/female

108/62 (64/36)

NA

NA

NA

NSAIDs, yes/no

87/83 (51/49)

56/52 (52/48)

31/31 (50/50)

.816

Biologicals, yes/no

67/103 (39/61)

45/63 (42/58)

22/40 (36/64)

.427

Corticosteroids, yes/no

12/158 (7/93)

6/102 (6/94)

6/56 (10/90)

.313a

DMARDs, yes/no

71/99 (42/58)

43/65 (40/60)

28/34 (45/55)

.496

Psychopharmacologic agents, yes/no

12/158 (7/93)

6/102 (6/94)

6/56 (10/90)

.313a

Analgesics, yes/no

73/97 (43/57)

33/75 (31/69)

40/22 (65/35)

< .00

Work status, yes/nob

99/64 (61/39)

64/38 (63/37)

35/26 (57/43)

.497

  1. Abbreviations: BMI Body mass index, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, normal value < 5 mg/L, HADS Hospital Anxiety and Depression Scale, NSAIDs Non-steroidal anti-inflammatory drugs, DMARDs Disease-modifying anti-rheumatic drugs, p<.05
  2. ap Value based on phi coefficient instead of chi Square test
  3. bn = 163 (9 males, 2 females missing)